

Michela Guardascione

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/25045/publications.pdf>

Version: 2024-02-01

20
papers

613
citations

623574

14
h-index

887953

17
g-index

21
all docs

21
docs citations

21
times ranked

1251
citing authors

#	ARTICLE	IF	CITATIONS
1	Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations. <i>Pharmaceutical Research</i> , 2021, 38, 759-778.	1.7	19
2	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	1.8	20
3	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1185, 122985.	1.2	16
4	Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6302.	1.8	16
5	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , 2020, 15, e0228822.	1.1	26
6	Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5498.	1.8	23
7	FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy. <i>Genes</i> , 2019, 10, 276.	1.0	9
8	The Genotype for <i>DPYD</i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	2.3	39
9	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3870-3896.	1.4	70
10	A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. <i>Cell Death and Differentiation</i> , 2018, 25, 2165-2180.	5.0	78
11	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1101.	1.6	8
12	Abstract 500: A p53/miR-30a/ZEB2 axis controls basal-like/triple-negative breast cancer aggressiveness. , 2018, , .		0
13	Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 147-158.	1.5	48
14	Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11579-11579.	0.8	0
15	1227 Risk of unplanned presentations and hospital admission of breast cancer outpatients. <i>European Journal of Cancer</i> , 2015, 51, S182.	1.3	0
16	1860 Last-line treatment of advanced breast cancer: Which clinical characteristics may predict the outcome?. <i>European Journal of Cancer</i> , 2015, 51, S285.	1.3	0
17	The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. <i>British Journal of Cancer</i> , 2015, 112, 1157-1165.	2.9	67
18	MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. <i>Future Oncology</i> , 2015, 11, 1201-1209.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Clinical advances in the development of novel VEGFR2 inhibitors. <i>Annals of Translational Medicine</i> , 2014, 2, 123.	0.7	121
20	Risk factors and survival outcomes in patients with brain metastases from breast cancer. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 951-956.	1.7	34